産婦人科学講座

• 講座概要
• 特徴的な臨床の取り組み
• 教授挨拶
• スタッフ
• 主な研究
• 主な業績

講座概要

女性の一生に寄り添う多様な医療を総合的に学ぶことができます。

1. 婦人科腫瘍学：標準治療から内視鏡手術やゲノム医療まで最先端の集学的癌治療について。
2. 生殖医療：リプロダクションセンターで行われる内分泌学検査から高度生殖補助医療について。
3. 周産期医学：正常・異常妊娠経過から母児集中管理センター（ＭＦＩＣＵ）での母児救命医療について。
4. ヘルスケア：月経機序、更年期障害、骨粗鬆症、代替支持療法など女性の健康管理についても幅広く。

特徴的な臨床の取り組み

婦人科診療

婦人科悪性・良性疾患に関する手術療法、薬物療法、放射線療法などの集学的治療を行っている。病院機能の観点から悪性疾患の治療を優先させていただいており、年間約250件の悪性疾患手術を行っている。良性疾患に対する手術療法には積極的に内視鏡手術を実施している。がん薬物療法は婦人科悪性腫瘍研究機構（JGOG）や厚生労働省管轄の日本臨床腫瘍研究グループ（JCOG）と共同体制下に新しい有効な薬剤を導入し、また、長期間の入院生活を避け、QOL向上のため短期入院や外来化学療法による治療を推進している。また、アメリカNCI（National Cancer Institute）、アメリカNRG Oncologyの認定施設として、欧米施設・アジア諸国とも連携して治療を行っており、婦人科がん分野では国内でも指導的立場を果たしている。漢方治療にも積極的に取り組んでおり、手術後や悪性腫瘍に対する化学療法などの際に生じる副作用対策診察を行っている。

産科診療

2001年4月1日、岩手医科大学附属病院に総合周産期母子医療センターが開設された。県全域を対象としてリスクの高い妊婦に対する医療や新生児医療を提供する施設で、岩手県においては1箇所のみに設置されている。総合周産期母子医療センターは母体・胎児集中治療室（MFICU）、新生児集中治療室（NICU）、新生児治療回復室（GCU）から成る。周産期部門としてはMFICU 9床と後方病床として産科病棟24床で、地域周産期医療センターや診療所と連携をとりながら、搬送が必要な妊婦さんは搬送コーディネーターが調整を行い24時間体制で入院受け入れを行っている。当院で行う周産期医療としては、合併症妊娠（重症妊娠高血圧症候群、前置癒着胎盤等）、胎児異常など母体または児におけるリスクの高い妊婦に対する医療、高度な新生児医療がある。必要に応じて当該施設の関係診療科または他の施設と連携して産科合併症以外の合併症（精神疾患、脳血管疾患、膠原病、心疾患、敗血症、外傷など）を有する母体にも対応している。MFICUでは高度な周産期医療を遂行するために、産科・小児科医師と医療スタッフが協力体制を築いている。また総合周産期母子医療センターに特化した産科医療として、（1）超音波検査とMRIを用いた出生前画像診断、（2）新生児集中治療室担当医・スタッフと治療についての定期カンファレンス、（3）妊娠28週未満の超早産への対応、（4）産科危機的出血に対する動脈塞栓術、（5）迅速な母体・胎児救命治療を目的とした超緊急帝王切開術の運用、（6）精神疾患合併妊娠の治療と支援を目的とした周産期リエゾンカンファレンスを行っている。

生殖部門診療

不妊症のカップルへのタイミング法や人工授精などの一般不妊治療、体外受精や顕微授精など高度生殖補助医療、不育症の検査・治療、子宮内膜症や子宮筋腫などの婦人科良性疾患に対する診断と治療を主に行っている。生殖医療に関する診療は内丸メディカルセンターで行っている。生殖医療専門医を中心に産婦人科専門医・卵子学会認定胚培養士など高い専門知識を持った人員を配置している。最近注目されている子宮内フローラ検査や、着床前検査（PGT-A/SR)も実施しており、がんなどの悪性腫瘍の患者さんに対する妊孕性温存目的の配偶子（卵子・精子）凍結も行っている。婦人科良性疾患に関する外来診療は内丸メディカルセンターで、手術療法は矢巾附属病院で行っている。手術はからだの負担の少ない内視鏡手術（腹腔鏡・子宮鏡・ロボット支援手術）に積極的に取り組んでいる。

教授挨拶

産婦人科は女性の健康に寄り添う。卵子から胎児、出生後も思春期、成人期、更年期、老年期と、女性はその多様なライフステージやライフスタイルの中で心身の揺らぎと疾患に直面する。産婦人科では1人1人の妊婦・患者について、病態だけでなく社会的背景に応じた個別化医療を提供する。そのためには幅広い医学的知識を蓄えるだけでなく、関連診療科や医療サービスと医療チームを構成し、牽引する実力を養わなければならない。

当科では、１）周産期医学、２）婦人科腫瘍学、３）生殖内分泌学、４）ヘルスケア学という産婦人科の4つの主要分野について体系的な教育を行っている。すなわち、産婦人科医療一般の習得を目指し、その後にどのような専門分野へ進んだとしても、女性の一生に寄り添った医療が提供できる人材の育成に努めている。

臨床医は現時点までに培われたエビデンスに基づく医療（EBM）を行うことに加え、EBMのさらなる改善を目指して最新の医療的知見を追求する姿勢が求められる。われわれは既存の検査法や治療法だけではなく、積極的に新しい検査や手術、未承認治療薬の開発・導入を進め、治療選択肢を増やしてきた。その結果、侵襲度の低い内視鏡手術や妊孕能温存手術、抗腫瘍免疫治療など20年前には想像もしなかった先進的な治療を数多く、提供することができるようになっている。この先に何が待ち構えているのか？治療を経て患者さんとそのご家族と一緒に慶びを分かち合う現場に数多く恵まれるよう、スタッフ一同、力をあわせて個別化医療の充実に邁進する。

講座スタッフ

教授	馬場　長	ばば　つかさ
特任教授	小山　理恵	おやま　りえ
特任教授	庄子　忠宏	しょうじ　ただひろ
准教授	利部　正裕	かがぶ　まさひろ
特任講師	岩動　ちず子	いするぎ　ちずこ
特任講師	永沢　崇幸	ながさわ　たかゆき
助教	尾上　洋樹	おのうえ　ひろき
助教	海道　善隆	かいどう　よしたか
助教	髙取　恵里子	たかとり　えりこ
助教	羽場　厳	はば　げん
助教	川村　花恵	かわむら　はなえ
助教	佐藤　翔	さとう　しょう
助教	佐藤　千絵	さとう　ちえ
助教	佐々木　佳夏子	ささき　かなこ
助教(任期付)	村上　一行	むらかみ　かずゆき
助教(任期付)	黒川　絵里加	くろかわ　えりか
助教(任期付)	佐藤　貴紀	さとう　たかのり
助教(任期付)	小木田　勇人	こぎた　はやと
助教(任期付)	鈴木　南奈子	すずき　ななこ
助教(任期付)	髙木　駿	たかぎ　しゅん
助教(任期付)	武蔵　実久	むさし　みく
助教(任期付)	吉田　光法	よしだ　みつのり
助教(任期付)	田付　駿介	たつき　しゅんすけ
専門研修医	徐　碧美	じょ　あみ
専門研修医	大野　妃香	おおの　ひめか
専門研修医	昆　夏鈴	こん　かりん
専門研修医	藤本　一	ふじもと　はじめ
大学院生	押切　実波	おしきり　みなみ
大学院生	細見　信悟	ほそみ　しんご
大学院生	外山　瑠璃子	そとやま　るりこ

講座における主たる研究テーマ

婦人科腫瘍部門

1. 卵巣がん、子宮体がん、子宮頸がんを対象とした婦人科がん治療の基礎的·臨床的検討
   • がんゲノムを軸とした薬剤耐性機序の解明（細胞周期・遺伝子）、浸潤・転移抑制の分子生物学的検討
   • 子宮がんを対象とした低侵襲手術（腹腔鏡手術・ロボット支援手術）、妊孕性温存手術
   • 治療抵抗性がんに対する新しい治療法の検討（分子標的治療、複合がん免疫治療）
2. 子宮内膜症·筋腫への新しい治療法確立の検討：新しいホルモン製剤と腹腔鏡手術の併用妥当性についての検討

周産期部門

1. 妊娠糖尿病・糖尿病合併妊娠の妊娠転帰および母児の長期予後に関する検討
2. 切迫早産と早産期陣痛の妊娠経過と分娩転帰に関する検討
3. 妊娠高血圧腎症における腟内・口腔内細菌叢とsFlt-1・PlGFとの関連性

生殖内分泌部門

1. 体外受精や内視鏡手術を含む総合的な不妊治療
2. 着床不全の病態と治療法の検討
   • 子宮内膜ポリープなどの子宮内環境の検討
   • 着床に関連する内分泌因子の分子生物学的検討
3. 体外受精にて正倍数性胚の獲得に必要な最適条件の検討
4. 女性の働き方の違いが体外受精に与える影響に関する検討

講座の主な業績

【令和７（2025）年度】

1. Kogita H, Oyama R, Haba G, Kawamura H, Baba T. The 24-Segment Global Sphericity Index Is Useful for Assessing Fetal Cardiac Function and as an Indicator of Fetal Well-Being.　Cureus. 2025 Dec 15;17(12):e99253. doi: 10.7759/cureus.99253.
2. Takatori E, Shoji T, Jo A, Musashi M, Tatsuki S, Jonai N, Chiba Y, Sato S, Kaido Y, Nagasawa T, Kagabu M, Takahashi F, Aida T, Baba T. Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective Study. Anticancer Res. 2025 Dec;45(12):5773-5783. doi: 10.21873/anticanres.17910.
3. Ito F, Shimokawa M, Sugiura A, Itani Y, Arakawa A, Inoue K, Onuki M, Shoji T, Egawa-Takata T, Takei Y, Takehara K, Motohashi T, Nagano H, Nakamura T, Munakata S, Yamada T, Furukawa N, Kita T, Ito K. Prognostic factors for malignant tumors arising from mature cystic teratomas: a study involving the Kansai Clinical Oncology Group (KCOG-G1305s study). Arch Gynecol Obstet. 2025 Dec;312(6):2333-2340. doi: 10.1007/s00404-025-08194-1.
4. Sato C, Onoue H, Nakamura S, Watanabe S, Koiwa K, Murakami K, Baba T. Status of fertility preservation therapy at Iwate Medical University Hospital and future challenges. Journal of Iwate Medical Association. 2025 Nov; 77(3):85-91. doi: 10.24750/iwateishi.77.3_85
5. Yagishita S, Sato S, Shintani D, Nishikawa T, Ogasawara A, Yasuda M, Ishii H, Furuuchi K, Uenaka T, Yoshida H, Hasegawa K, Hamada A. Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models. Mol Cancer Ther. 2025 Nov 3;24(11):1789-1801. doi: 10.1158/1535-7163.MCT-25-0035.
6. Toyoshima M, Akira S, Kumakiri J, Baba T, Saito J, Terai Y, Horibe Y, Terao Y, Mandai M. Guidelines for Endoscopic Surgery in Obstetrics and Gynecology 2024 by Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy: A Secondary Publication Based on the Japanese Edition. Gynecol Minim Invasive Ther. 2025 Jul 19;14(3):201-206. doi: 10.4103/gmit.GMIT-D-25-00031.
7. Hirakawa T, Kato T, Nakanishi Y, Urushiyama D, Miyata K, Baba T, Ohno H, Yasunaga S, Yotsumoto F, Miyamoto S. Proteomic and Metabolomic Analyses of Adipose-derived Mesenchymal Stem Cell Exosomes and Culture Supernatants. Anticancer Res. 2025 Aug;45(8):3409-3424. doi: 10.21873/anticanres.17703.
8. Sato S, Yagishita S, Yoshida H, Shintani D, Ogasawara A, Nishikawa T, Yasuda M, Furuuchi K, Uenaka T, Hamada A, Hasegawa K. Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling. Neoplasia. 2025 Jun;64:101158. doi: 10.1016/j.neo.2025.101158.
9. Hirakawa T, Nakabayashi K, Ito N, Ishiwata K, Urushiyama D, Miyata K, Baba T, Hata K, Yasunaga S, Yotsumoto F, Tachibana K, Miyamoto S. Culture Medium Enriched with Ultrafine Carbon Monoxide Bubbles Enhances In Vitro Blastocyst Formation of In Vivo-Fertilized Mouse Zygotes. Antioxidants (Basel). 2025 Jun 4;14(6):684. doi: 10.3390/antiox14060684.
10. Morisada T, Kobayashi Y, Nagase S, Baba T, Tokunaga H, Watari H, Takekuma M, Terao Y, Terai Y, Kajiyama H, Asai-Sato M, Takehara K, Tabata T, Harano K, Hirashima Y, Yunokawa M, Okamoto A, Mikami M. Japan Society of Gynecologic Oncology 2023 guidelines for treatment of uterine body neoplasm. J Gynecol Oncol. 2025 May;36(3):e119. doi: 10.3802/jgo.2025.36.e119.
11. Sato S, Shintani D, Kaneda Y, Nakamura R, Katoh T, Yano M, Hanaoka M, Yagishita S, Yasuda M, Nagata M, Hasegawa K. Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma. Int J Clin Oncol. 2025 Apr;30(4):805-813. doi: 10.1007/s10147-024-02658-1.
12. Tanaka T, Takehara K, Usami T, Ishikawa M, Kondo E, Kagabu M, Hirabayashi K, Matsumura N, Sato S, Nishimura M, Arakawa A, Nakamura K, Konno Y, Fujiwara S, Sueoka K, Nakamura H, Koh I, Ito K, Hongo A. Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study. Gynecol Oncol Rep. 2025 Apr 9;59:101740. doi: 10.1016/j.gore.2025.101740.
13. Sagae Y, Yamanoi K, Horie A, Kaneda M, Sunada M, Miyamoto T, Mizuno R, Taki M, Murakami R, Yamaguchi K, Hamanishi J, Baba T, Terai Y, Yokoyama Y, Kondo E, Kobayashi H, Mandai M. Online Live Streaming System for Robotic Surgery With Bidirectional Discussion Through a Commentator: A Multi-Institutional Observational Study. Asian J Endosc Surg. 2025 Jan-Dec;18(1):e70072. doi: 10.1111/ases.70072.
14. Onoue H, Murakami K, Sato C, Kaido Y, Nagasawa T, Kagabu M, Baba T. Robot-Assisted Laparoscopic Repair for Recurrence After Robot-Assisted Laparoscopic Sacrocolpopexy: A Case Report. Asian J Endosc Surg. 2025 Jan-Dec;18(1):e70057. doi: 10.1111/ases.70057.
15. Kakuwa T, Rikitake R, Nagase S, Mikami M, Baba T, Kaneuchi M, Tokunaga H, Seino M, Muramatsu T, Yamagami W, Takehara K, Niikura H, Hirashima Y, Yoshino K, Ichinose Y, Kawata A, Higashi T. Revision of quality indicators for cervical cancer and trend analysis of existing indicators in Japan. J Gynecol Oncol. 2025 Sep;36(5):e78. doi: 10.3802/jgo.2025.36.e78.
16. Konishi I, Abiko K, Hayashi T, Koshiyama M, Matsumura N, Baba T, Yamanoi K, Yamaguchi K, Hamanishi J, Mandai M. Ovarian cancer screening: where do we stand now? Academia Oncology. 2025;2(1). doi:10.20935/AcadOnco7488
17. Baba T, Hiraike O, Iwase A, Tanimura S, Sunada M, Takenaka S, Horie A, Nishi H, Mandai M. Current trends and challenges in minimally invasive surgical treatment for gynecologic cancers in Japan: a cancer statistics report. Int J Clin Oncol. 2025 May;30(5):837-843. doi: 10.1007/s10147-025-02735-z.
18. Yamaguchi K, Jiang M, Miyamoto T, Mizuno R, Taki M, Yamanoi K, Murakami R, Hamanishi J, Hosoe Y, Baba T, Matsumura N, Konishi I, Fujii S, Mandai M. Epigenetic dispositions in ovarian clear cell carcinoma: a nexus of genomic, epigenetic, and metabolic alterations. Academia Oncology. 2025;2(2). doi:10.20935/AcadOnco7749
19. Jo A, Shoji T, Otsuka H, Abe M, Tatsuki S, Chiba Y, Sato S, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Baba T. Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors. Int J Clin Oncol. 2025 Feb;30(2):229-240. doi: 10.1007/s10147-024-02689-8.
20. Ito R, Kagabu M, Sato S, Takatori E, Kaido Y, Nagasawa T, Shoji T, Hirayama T, Terao Y, Baba T. Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients. Int J Clin Oncol. 2025 Mar;30(3):559-569. doi: 10.1007/s10147-024-02682-1.
21. Kaido Y, Jonai N, Oshikiri M, Murakami K, Sato S, Takatori E, Onoue H, Nagasawa T, Kagabu M, Shoji T, Baba T. Laparoscopic repair of obturator nerve injury during pelvic lymphadenectomy: a case report. Obstet Gynecol Int J. 2025;16(1):29‒30. DOI: 10.15406/ogij.2025.16.00783

【令和６（2024）年度】

1. Chiba, Y., Kagabu, M., Osakabe, M., Ito, R., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Shoji, T., *Yanagawa, N., Baba, T.: A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system. Jpn J Clin Oncol. 54(4):424–433(2024)
2. *Maekawa, S,. *Takata, R,. * Sekiguchi, K,. Kagabu, M,. * Toyoshima, M,. *Tamada, S,. *Takahashi, K,. *Ikarashi, D,. *Matsuura, T,. *Kato, R,. *Kato, Y,. *Kanehira, M,. *Sugimura, J,. *Abe, T,. Baba, T,. Obara, W,: Prevalence of germline BRCA1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice. Jpn J Clin Oncol. 54(4):489-497(2024) 
3. *Hirakawa, T., *Nakabayashi, K., * Ito, N., *Hata, K., *Imi, S., *Shibata, M., *Urushiyama, D., *Miyata, K., *Yotsumoto, F., *Yasunaga, S., Baba, T., *Miyamoto, S.: Transwell Culture with Adipose Tissue-Derived Stem Cells and Fertilized Eggs Mimics the In Vivo Development of Fertilized Eggs to Blastocysts in the Fallopian Tube: An Animal Study. Antioxidants. 13(6):704(2024)
4. *Furutake, Y., *Yamaguchi, K., *Yamanoi, K., *Kitamura, S., *Takamatsu, S., *Taki, M., *Ukita, M., *Hosoe, Y., *Murakami, R., *Abiko, K., *Horie, A., *Hamanishi, J., Baba, T., *Matsumura, N., *Mandai, M.: YAP1 suppression by ZDHHC7 is associated with ferroptosis resistance and poor prognosis in ovarian clear cell carcinoma. Mol Cancer Ther.2024;23(11):1652-1665. 
5. *Ueda, A., *Nakai, H., *Miyagawa, C., *Otani, T., *Yoshida, M., *Murakami, R., *Komiyama, S., *Tanigawa, T., *Yokoi, T., *Takano, H., Baba, T., *Miura, K., *Shimada, M., *Kigawa, J., *Enomoto, T., *Hamanishi, J., Okamoto, A., *Okuno, Y., *Mandai, M., *Matsumura, N.: Artificial intelligence-based histopathological subtyping of high-grade serous ovarian cancer. Am J Pathol. 194(10):1913–1923(2024)
6. *Hirakawa, T., *Yotsumoto, F., *Imi, S., *Ito, N., *Ishiwata, K., *Nakabayashi, K., *Watanabe, A., *Shirasu, N., *Urushiyama, D., *Miyata, K., *Takahashi, S., Baba, T., *Hata, K., *Yasunaga, S., *Miyamoto, S.: Adipose-derived Mesenchymal Stem Cell Transplantation Improves Ovarian Function and Oocyte Quality in Aged Mice. Anticancer Res. 44(8):3577–3586(2024).
7. *Takamatsu, S., *Hillman, R.T., *Yoshihara, K., Baba, T., *Shimada, M., *Yoshida, H., *Kajiyama, H., *Oda, K., *Mandai, M., *Okamoto, A., *Enomoto, T., *Matsumura, N.: Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study. Br J Cancer. 131(8):1340–1349(2024)
8. *Matsumura, Y., *Futagami, M., Baba, T., *Soeda, S., *Watari, H., *Terada, Y., *Tokunaga, H., *Nagase, S., *Nakanishi, T., *Kaiho, M., *Yokoyama, Y.: Effectiveness of the Traditional Japanese Medicine Goshajinkigan in Preventing Paclitaxel-Induced Peripheral Neuropathy: A Multicenter Randomized Comparative Trial. Integr Cancer Ther. 23:15347354241278635(2024)
9. Shoji, T., Takatori, E., Nagasawa, T., Kagabu, M., Baba, T., *Shigeto, T., *Matsumura, Y., *Shimizu, D., *Terada, Y., *Seino, M., *Ohta, T., *Nagase, S., *Shigeta, S., *Tokunaga, H., *Shimada, M., *Kaiho-Sakuma, M., *Furukawa, S., *Soeda, S., *Watanabe, T., *Takahashi, F., *Yokoyama, Y.: Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study). Cancers (Basel). 16(22):3801(2024)
10. *Takahashi, N., *Seki, T., *Sasaki, K., *Machida, R., *Ishikawa, M., *Yunokawa, M., *Matsuoka, A., Kagabu, M., *Yamaguchi, S., *Hiranuma, K., *Ohnishi, J., *Sato, T.: High cost of chemotherapy for gynecologic malignancies. Jpn J Clin Oncol. 54(10):1078–1083(2024)
11. *Nishijima, A,. *Oda, K,. *Hasegawa, K,. *Koso, T,. *Asada, K,. *Ikeda, Y,. *Taguchi, A,. *Maeda, D,. *Nagae, G,. *Tsuji, S,. *Tatsuno, K,. *Uehara, Y,. *Kurosaki, A,. Sato, S,. *Tanikawa, M,. *Sone, K,. *Mori, M,. *Ikemura, M,. *Fujiwara, K,. *Ushiku, T,. *Osuga, Y,. *Aburatani, H,: Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin. Sci Rep. 14(1):18797(2024)
12. Ito, R., Kagabu, M., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Shoji, T., *Hirayama, T., *Terao, Y., Baba, T.: Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients. Int J Clin Oncol. 30(3):559–569(2025)
13. *Kakuwa, T., *Rikitake, R., *Nagase, S., *Mikami, M., Baba, T., *Kaneuchi, M., *Tokunaga, H., *Seino, M., *Muramatsu, T., *Yamagami, W., *Takehara, K., *Niikura, H., *Hirashima, Y., *Yoshino, K., *Ichinose, Y., *Kawata, A., *Higashi, T.: Revision of quality indicators for cervical cancer and trend analysis of existing indicators in Japan. J Gynecol Oncol. 36:e78(2025)
14. *Konno, Y., *Ohnishi, S., *Minobe, S., *Nomura, E., Nagasawa, T., *Fujimoto, E., *Ohara, T., *Nishio, S., *Kato, H., *Yokoyama, Y., *Miyagi, E., *Tokunaga, H., *Nishino, K., *Kikuchi, A., *Yoshida, Y., *Iwata, T., *Noguchi, D., *Kudaka, W., *Oyamada, S., *Ariyoshi, K., *Kihara, K., *Watari, H.: Efficacy of Rikkunshito on chemotherapy-induced nausea and vomiting in patients with uterine corpus or cervical cancer treated with cisplatin-based regimen—placebo-controlled, double-blind, randomized confirmatory study (JORTC-KMP03). Integr Cancer Ther. 24:15347354251329346(2025)
15. Sato C, Onoue H, Nakamura S, Watanabe A,  Koiwa K, Murakami K, Baba T.: Status of fertility preservation therapy at Iwate Medical University Hospital and future challenge. Journal of Iwate Medical Association. In press.
16. Sato, S,. *Miura, T,. *Ogasawara, A,. *Shintani, D,. *Yamaguchi, S,. *Inui, H,. *Yoshinaga, A,. *Nishiyama, M,. *Tsugane, M,. *Hasegawa, K,: Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential. J Gynecol Oncol. 36(2):e24(2025)
17. Sato, S,. *Shintani, D,. *Kaneda, Y,. *Nakamura, R,. *Katoh, T,. *Yano, M,. *Hanaoka, M,. *Yagishita, S,. *Yasuda, M,. *Nagata, M,. *Hasegawa, K,: Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma. Int J Clin Oncol. 30(4):805–813(2025)
18. *de Santiago, P.R,. Sato, S,. *Zhang, S.J,. *Dougher, M.C,. *Devins, K.M,. *Bilecz, A.J,. *Rayamajhi, S,. *Mingo, G,. *Rendulich, H.S,. *Feng, Y,. *Wu, C,. *Taylor, M.S,. *Zhuravlev, Y,. * Jung, E,. *Omran, D.K,. *Wang, T.L,. *Shih, I.M,. *Schwartz, L.E,. *Kim, S,. *Morgan, M.A,. *Tanyi, J.L,. *Burns, K.H,. *Lengyel, E,. *Parra-Herran, C,. *Godwin, A.K,. *Walt, D.R,. *Drapkin, R,: LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker. NPJ Precis Oncol. 9(1):62(2025)

【令和５（2023）年度】

1. *Takamatsu, S.,*Yoshihara, K.,  Baba, T.,*Shimada,    M.,*Yoshida, H.,*Kajiyama, H.,*Oda, K.,*Mandai,  M.,*Okamoto, A.,*Enomoto, T.,*Matsumura, N.: Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma.  JGOG3025-TR2 study. Br J Cancer.:  128(6): 1095-1104.(2023)
2. *Yoshihara, K.,  Baba, T.,*Tokunaga, H.,*Nishino, K.,*Sekine, M.,* Takamatsu, S.,*Matsumura, N.,*Yoshida,H.,* Kajiyama, H.,*Shimada, M.,*Kagimura, T.,*Oda, K.,  *Sasajima, Y.,*Yaegashi, N.,*Okamoto, A.,* Sugiyama, T.,*Enomoto, T.: Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: JGOG3025 study. Cancer Sci.: 114(6): 2515-2523(2023) 
3. Baba, T.,*Koshiyama, M., Kagabu, M.,*Mikami, Y.,*Minamiguchi, S.,*Moritani, S.,*Ishikawa, M., *Okamoto, A.,*Terao, Y.,*Nakanishi, T., *Katabuchi, H.,*Tokunaga, H.,*Satoh, T.,*Konishi, I.,*Yaegashi, N.: Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study. Int J Clin Oncol.:  28(10): 1411-1420(2023)
4. *Akashi, H.,*Yachida, N.,*Ueda, H.,*Yamaguchi, M.,*Yamawaki, K.,*Tamura, R.,*Suda, K.,*Ishiguro, T.,*Adachi, S.,*Nagase, Y.,*Ueda, Y.,*Ueda, M.,*Abiko, K., Kagabu, M.,  Baba, T.,*Nakaoka, H., *Enomoto, T.,*Murai, J.,*Yoshihara, K.: SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma. Mol Cancer Ther. 23(1): 106-116(2024)
5. *Miyamoto, S.,*Hirakawa, T.,*Noguchi, Y., *Urushiyama, D.,*Miyata, K.,  Baba, T.,*Yotsumoto,  F.,*Yasunaga, S.,*Nakabayashi, K.,*Hata, K., *Nakagawa, W.,*Otsuka, T.,*Nozawa, Y.,*Furuhata, I.,*Mikasa, J.:  Physical Properties of Ultrafine Bubbles Generated Using a Generator System. In Vivo.: Nov-Dec;37(6): 2555-2563(2023)
6. Nagasawa, T., Shoji, T., Takatori, E., Kaido, Y., Kagabu, M.,*Shimizu, D.,*Shigeto ,T., Baba, T.,* Sugiyama, T.,*Yokoyama, Y.: A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study). Cancers (Basel).: 15(21): 5201(2023)
7. *Seino, M.,*Nagase, S.,*Tokunaga, H.,*Yamagami,  W.,*Kobayashi, Y.,*Tabata, T.,*Kaneuchi, M., *Hirashima, Y.,*Niikura, H.,*Yoshino, K.,*Takehara, K.,  Baba, T.,*Katabuchi, H.,*Mikami, M.: Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment. J Gynecol Oncol.: 35(1): e15(2024)
8. *Abe, M., Shoji, T., Chiba, Y., Takatori, E., Kaido, Y., Nagasawa, T.,  Kagabu, M.,*Takahashi, F.,*Aida, T., Baba, T.: Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. Anticancer Res. 43(3):  1265-1272(2023)
9. Jonai, N., Shoji, T.,*Kanasugi, T.,*Yodogawa, Y., *Takeshita, R.,*Ito, R.,*Abe, M.: Efficacy of Granisetron in the Treatment of Nausea and Vomiting Post-Cesarean Section (A Single Centre Retrospective Cohort Study). Gynecol Obstet Open Acc.: 7: 154(2023)
10. Chiba, Y., Kagabu, M., Osakabe, M.,*Ito, R., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Shoji, T.,*Yanagawa, N., Baba, T.: A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system. Jpn J Clin Oncol.: Jan 20: hyad192(2024)
11. *Sakai, H.,*Itani, Y., Nagasawa, T.,*Yoshida, Y., et al.: Protocol for a Prospective Cohort Study to Evaluate Changes in Sexuality in Patients With Primary Cervical Cancer Using Patient-Reported Outcomes (JGOG9004, SARAH Study), and Our Approaches to Solving the Unmet Needs of Patients With Gynecological Cancer. J Clin Gynecol Obstet.: 12(2): 59-64(2023)
12. *Komatsu, H.,*Matsumoto, K., Nagasawa, T., *Sato, T., et al.: A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study. Cancer Medicine.: 13:e6968(2024) 
13. Sato, S.,*Gillette, M.,*Santiago, P,.*Kuhn, Eric., *Burgess, M.,*Doucette, Kristen.,*Feng, Yi., *Dorantes, C.,*Ippoliti, Paul.,*Hobday, S.,* Mitchell, M.,*Doberstein, K.,*Gysler, S.,*Hirsch,  M.,*Schwartz, L.,*Birrer, M.,*Skates, S.,*Burns,  K.,*Carr, S.,*Drapkin, R.: LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Sci Rep.: 13(1):1537(2023)
14. *Yagishita, S.,*Nishikawa, T.,*Yoshida, H.,* Shintani, D., Sato, S.,*Miwa, M.,*Suzuki, M.,* Yasuda, M.,*Ogitani, Y.,*Jikoh, T.,*Yonemori, K.,*Hasegawa, K.,*Hamada, A.: Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy. Clin Cancer Res.: 13;29(12):　2239-2249(2023)

【令和４（2022）年度】

1. *Miyamoto, T., *Murakami, R., *Hamanishi, J., *Tanigaki, K.., *Hosoe, Y., *Mise, N., *Takamatsu,S., *Mise, Y., *Ukita, M., *Taki, M., *Yamanoi, K., *Horikawa, N., *Abiko, K., *Yamaguchi, K., Baba, T., Matsumura, N., Mandai, M.: B7-H3 suppresses anti-tumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression. Cancer Immunol Res. : 10(1): 56-69(2022)
2. *Konishi, A., *Samura, O., *Muromoto, J., *Okamoto, Y., *Takahashi, H., *Kasai, Y., *Ichikawa, M., *Yamada, N., *Kato, N., *Sato, H., *Hamada, H., *Nakanami, N., *Machi, M., *Ichizuka, K., *Sunami, R., *Tanaka, T., *Yonetani, N., *Kamei, Y., *Nagamatsu, T., *Matsumoto, M., *Tairaku, S., *Fujiwara, A., *Nakamura, H., *Harada, T., *Watanabe, T., *Sasaki, S., *Kawaguchi, S., *Minami, S., *Ogawa, M., *Miura, K., *Suzumori, N., *Kojima, J., *Kotani, T., *Sasaki, R., Baba, T., *Toyofuku, A., *Endo, M., *Takeshita, N., *Taketani, T., *Sase, M., *Matsubara, K., *Hayata, K., *Hamada, Y., *Egawa, M., *Kakinuma, T., *Matsushima, S., *Kitagawa, M., *Shiga, T., *Kurashina, R., *Hamada, H., *Takagi, H., *Kondo, A., *Miharu, N., *Yamashita, M., *Horiya, M., *Morimoto, K., *Takahashi, K., *Okamoto, A., *Sekizawa, A., *Sago, H.: Prevalence of common aneuploidy in twin pregnancies.: J Hum Genet.: 67(5): 261-265(2022)
3. *Nagase, S., *Ohta, T., *Takahashi, F., *Yamagami, W., *Yaegashi, N., *Enomoto, T., *Katabuchi, H., *Kawana, K., *Kobayashi, H., *Kobayashi, Y., *Shozu, M., Baba, T., *Morishige, K., *Yoshida, Y., *Yoshino, K., *Tokunaga, H.: Annual report of the Committee on Gynecologic Oncology. the Japan Society of Obstetrics and Gynecology. Annual Patient Report for 2018 and Annual Treatment Report for 2013. J Obstet Gynaecol Res.: 48(3): 541-552(2022)
4. *Mise, Y., *Hamanishi, J., *Daikoku, T., *Takamatsu, S., *Miyamoto, T., *Taki, M., *Yamanoi, K., *Yamaguchi, K., *Ukita, M., *Horikawa, N., *Abiko, K., *Murakami, R., *Furutake, Y., *Hosoe, Y., *Terakawa, J., Kagabu, M., *Sugai, T., *Osakabe, M., *Fujiwara, H., *Matsumura, N., *Mandai, M., Baba, T.: mmunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells.: Carcinogenesis.: 43(7): 647–658(2022) 
5. Ukita, M., Hamanishi, J., Yoshitomi, H., Yamanoi, K., Takamatsu, S., Ueda, A., Suzuki, H., Hosoe, Y., Furutake, Y., Taki, M., Abiko, K., Yamaguchi, K., Nakai, H., Baba, T., Matsumura, N., Yoshizawa, A., Ueno, H., Mandai, M.: CXCL13-producing CD4+ T cells accumulate in early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight.: 7(12): e157215(2022)
6. Tatsuki, S., Shoji, T., Abe, M., Tomabechi, H., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., Aida, T., Baba, T.: Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer. A Multicenter Retrospective Study. Anticancer Res.: 42(9): 4603-4610(2022)
7. Shoji, T., Takatori, E., Nagasawa, T., Kagabu, M., Baba, T., *Shigeto, T., *Matsumura, Y., *Shimizu, D., *Terada, Y., *Seino, M., *Ohta, T., *Nagase, S., *Shigeta, S., *Tokunaga, H., *Shimada, M., *Kaiho-Sakuma, M., *Furukawa, S., *Soeda, S., *Watanabe, T., *Takahashi, F., *Yokoyama, Y.: Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study). Int J Clin Oncol.: 27(12): 1874-1880(2022)
8. *Sato, T., Oyama, R., Baba, T.: Fulminant streptococcal infection with earlyimmunoglobulin introduction resulting in a favourableoutcome for both mother and new‐born. A case report. Reprod Female Child Health.: 1‐4.doi: 10.1002/rfc2.144(2022)
9. *Kogita, H., Oyama, R., Sato, T., Kikuchi, K., *Hosomi, S., Terata, M., Kawamura, H., Haba, G., Isurugi, C., Baba, T., *Kurokawa, E., Oyama, S.: Multi-Professional Collaboration for a Fetal Anomaly in an Adolescent Pregnancy. A Case Report. Gynecol Obstet Open Acc.: 6: 151(2022) 
10. Oyama, R., *Chiba, T., *Yamada, H.: (Eds) Pregnancy and Breastfeeding.Internal Medicine for Dental Treatments. Patients with Medical Diseases.: Chapter19. SpringerNature. in press (2023)
11. Shoji, T., *Enomoto, T., *Abe, M., *Okamoto, A., Nagasawa, T., *Oishi, T., *Nagase, S., *Mori, M., *Inokuchi, Y., *Kamiura, S., *Komiyama, S., *Takeshima, N., *Sugiyama, T.: Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab. The Japanese Gynecologic Oncology Group study JGOG3023. Cancer Sci.: Jan;113(1):240-250.(2022)
12. *Egawa-Takata, T., *Ueda, Y., *Ito, K., *Hori, K., Shoji, T., Nagasawa, T., *Nishio, S., *Ushijima, K., *Koji, N., *Enomoto, T., *Kikuchi, A., *Honma, S., *Oishi, T., *Shimada, M., *Takei, Y., *Fujiwara, H., *Tanabe, H., *Okamoto, A., *Nishio, Y., *Yamada, T., *Kimura, T.: Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma. Cancer Sci.: May;113(5): 1693-1701(2022)
13. *Tanigawa, T., *Takeshima, N., *Ishikawa, H., *Nishio, S., *Usami, T., *Yamawaki, T., *Oishi, T., *Ihira,K., *Kato, H., *Goto, M., *Saito, M., *Taira, Y., *Yokoyama, M., Shoji, T., *Kondo, E., *Mori, A., *Yokoi, T., *Iwasa-Inoue, N., *Hirashima, Y., Nagasawa, T., *Takenaka, M., *Mikami, M., *Sugiyama, T., *Enomoto, T.: Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079). Gynecol Oncol.: Jun;165(3): 413-419(2022)
14. *Abe, M., Shoji, T., Chiba, Y., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., *Takahashi, F., *Aida, T., Baba, T.: Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. Anticancer Res.: Mar;43(3): 1265-1272(2023)
15. *Jonai, N., Shoji, T., *Kanasugi, T., *Yodogawa, Y., *Takeshita, R., *Ito, R., *Abe, M.: Efficacy of Granisetron in the Treatment of Nausea and Vomiting Post-Cesarean Section (A Single Centre Retrospective Cohort Study). Gynecol Obstet Open Acc.: 7: 154(2023)
16. *Ito, K., *Nakagawa, M., *Shimokawa, M., *Hori, K., *Tashima, L., *Goto, M., *Yanagida, S., *Suzuki, J., *Kaya, R., *Kawabata, A., *Yamada, K., *Park, J., *Nasu, H., *Nishio, S., *Kondo, E., *Kaneda, M., *Tsubamoto, H., *Arakawa, A., Nagasawa, T., *Motohashi, T.: Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601. Anticancer Drugs.: Dec 5.doi:10: 1097(2022)
17. Kawamura, H., *Naoto, Y., Murakami, K., *Kawamura, H., *Sugiyama, I., *Sasaki, Y., *Odagiri, T., *Sadzuka, Y., *Muraki, Y.: The relationship between the chemical structure, physicochemical properties, and mucosal adjuvanticity of sugar-based surfactants. European Journal of Pharmaceutics and Biopharmaceutics.: 2023 January.: Volume 182: 1-11(2023)
18. Chiba, Y., *Sudo, K., *Kojima, Y., *Okuma, H., *Kohsaka, S., *Machida, R., *Ichimura, M., *Anjo, K., *Kurishita, K., *Okita, N., *Nakamura, K., *Kinoshita, I., *Takahashi, M., *Matsubara, J., *Kusaba, H., *Yonemori, K., *Takahashi, M.: A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial: BMC Cancer: volume 22, Article number: 869 (2022) Cite this article esses 2 Citati ons Metrics 

【令和３（2021）年度】

1. *Mise Y, *Hamanishi J, *Daikoku T, *Takamatsu S, *Miyamoto T, *Taki M, *Yamanoi K,* Yamaguchi K,* Ukita M,* Horikawa N,* Abiko K, *Murakami R,* Furutake Y, *Hosoe Y, *Terakawa J, Kagabu M, *Sugai T, Osakabe M, *Fujiwara H, *Matsumura N, *Mandai M, Baba T. Immunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells. Carcinogenesis.30:bgac032. doi: 10.1093/carcin/bgac032(2022)
2. *Miyamoto T, *Murakami R,* Hamanishi J, *Tanigaki K, *Hosoe Y, *Mise N, *Takamatsu S, *Mise Y,* Ukita M, *Taki M, *Yamanoi K,* Horikawa N,* Abiko K, *Yamaguchi K, Baba T, *Matsumura N, *Mandai M. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. Cancer Immunol Res.10(1):56-69(2022)
3. *Kitamura S, *Yamaguchi K, *Murakami R, *Furutake Y, *Higasa K,* Abiko K, *Hamanishi J, Baba T, *Matsumura N, *Mandai M.PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma. Cancer Sci.112(11):4627-4640(2021) 
4. *Horie A, *Abiko K, Baba T, Sunada M, *Kitamura S, Yamanoi K, *Horikawa N, *Yamaguchi K, *Hamanishi J, *Kondoh E, *Mandai M. J Minim Invasive Gynecol;28(8):1444-1445(2021)
5. *Murakami R, *Hamanishi J, *Brown JB, *Abiko K, *Yamanoi K, *Taki M, *Hosoe Y, *Yamaguchi K, Baba T, *Matsumura N,Konishi I, *Mandai M.Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. Sci Rep. 1;11(1):11427.(2021)
6. *Togami S, *Kobayashi H, *Niikura H, *Shimada M, *Susumu N, *Tanaka T, *Terai Y, *Nagai T, Baba T, *Yahata H, *Yamagami W, *Yamaguchi K, *Yamashita T, *Yaegashi N, *Katabuchi H, *Aoki D.Survey of the clinical practice pattern of using sentinel lymph node biopsy in patients with gynecological cancers in Japan: the Japan Society of Gynecologic Oncology study. Int J Clin Oncol.26(5):971-979(2021)
7. *Akihito H, *Kaoru A, Tsukasa B, *Masumi S, *Sachiko K, *Koji Y, *Naoki H4, *Ken Y, *Junzo H, *Eiji K, *Masaki M. A Novel Direct Approach to the Deep Uterine Vein in Laparoscopic Radical Hysterectomy. J Minim Invasive Gynecol.28(8):1444-1445.doi: 10.101(2020)
8. Kagabu M, Nagasawa T, Tatsuki S, Fukagawa Y, Tomabechi H, Takatori E, Kaido Y, Shoji T, Baba T. Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study. May29;57(6):548(2021)
9. *Ishikawa M, *Shibata T, *Iwata T, *Nishio S, *Takada T, *Suzuki S, *Horie K, *Kudaka W, Kagabu M, *Tanikawa M, *Kitagawa R, *Takekuma M, *Kobayashi H, *Yaegashi N; Japan Clinical Oncology Group. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis. Gynecol Oncol.17:S0090-8258(21)00403-0(2021)
10. Kagabu M, *Yoshino N, *Saito T, *Miura Y, *Takeshita R, *Murakami K, *Kawamura H, Baba T & *Sugiyama T.The efficacy of a third-generation oncolytic herpes simplex viral therapy for an HPV-related uterine cervical cancer model. Int Jof Clin Oncol.26:591–597(2021)
11. Shoji T, *Kikuchi K, *Kogita H, *Jonai N, *Tomabechi H, *Kudoh A, Takatori E, Nagasawa T, *Sato S, Kagabu M, Baba T. New treatment strategy for ovarian cancer with a BRCA gene mutation. Eur J Gynaecol Onco.l42: 1-9.(2021)
12. *Shimada M, *Sato S, Shoji T, *Nagao S, *Tokunaga H, *Sueoka K,* Takehara K, *Nakamura K, *Yamaguchi S, *Kigawa J. Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study. Int J Clin Oncol.26(7):1314-1321(2021)
13. Shoji T, *Enomoto T, *Abe M, *Okamoto A, Nagasawa T, *Oishi T, *Nagase S, *Mori M, *Inokuchi Y, *Kamiura S, *Komiyama S, *Takeshima N, *Sugiyama T. Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab The Japanese Gynecologic Oncology Group study JGOG3023. Cancer Sci. 113(1):240-250(2022) 
14. *Egawa-Takata T, *Ueda Y, *Ito K, *Hori K, Shoji T, Nagasawa T, *Nishio S, *Ushijima K, *Koji N, *Enomoto T, *Kikuchi A, *Honma S, *Oishi T, *Shimada M, *Takei Y, *Fujiwara H, *Tanabe H, *Okamoto A, *Nishio Y, *Yamada T, *Kimura T. Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma. Cancer Sci. 113(5):1693-1701(2022)